Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series

Abstract : The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common adverse events of PFD are skin manifestations (25%), described as photosensitivity or rash, but they are not well characterized. The objective of the present real-life study was to address the question of skin manifestations in patients treated with PFD for IPF.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01771415
Contributor : Laurent Jonchère <>
Submitted on : Thursday, April 26, 2018 - 1:43:16 PM
Last modification on : Tuesday, May 7, 2019 - 6:30:15 PM
Long-term archiving on : Tuesday, September 25, 2018 - 1:46:59 PM

File

Pirfenidone photosensitization...
Files produced by the author(s)

Identifiers

Citation

C Droitcourt, Henri Adamski, A Polat, E Polard, M Kerjouan, et al.. Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis a case series. British Journal of Dermatology, Wiley, 2018, 178 (3), pp.e222-e223. ⟨10.1111/bjd.16016⟩. ⟨hal-01771415⟩

Share

Metrics

Record views

206

Files downloads

88